Therapeutic Efficacy and Adverse Events of Tacrolimus in Patients with Crohn’s Disease: Systematic Review and Meta-Analysis

Evidence-based clinical practice guidelines for inflammatory bowel disease

(2018) Katsuyoshi Matsuoka et al.   JOURNAL OF GASTROENTEROLOGY

Tacrolimus Exerts Only a Transient Effectiveness in Refractory Pediatric Crohn Disease

(2017) Oriane Truffinet et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti–Tumor Necrosis Factor Agents

(2016) Pauline Wils et al.   Clinical Gastroenterology and Hepatology

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management

(2016) Fernando Gomollón et al.   Journal of Crohns & Colitis

Asia-Pacific consensus statements on Crohn's disease. Part 2: Management

(2015) Choon Jin Ooi et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation

(2015) L. Shamseer et al.   BMJ-British Medical Journal

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation

(2015) L. Shamseer et al.   BMJ-British Medical Journal

A Questionnaire-Based Survey on the Diagnosis and Management of Inflammatory Bowel Disease in East Asian Countries in 2012

(2014) Nobuyuki Hida et al.   DIGESTION

Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

(2014) Bruce E. Sands et al.   GASTROENTEROLOGY

The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation

(2013) Dennis A. Hesselink et al.   CLINICAL PHARMACOKINETICS

Tacrolimus Salvage in Anti–Tumor Necrosis Factor Antibody Treatment-Refractory Crohn’s Disease

(2013) Mark E. Gerich et al.   INFLAMMATORY BOWEL DISEASES

Oral Tacrolimus for the Treatment of Refractory Inflammatory Bowel Disease in the Biologic Era

(2013) Lena W. Y. Thin et al.   INFLAMMATORY BOWEL DISEASES

Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients

(2013) Jun Miyoshi et al.   Journal of Crohns & Colitis

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients

(2012) K. J. Schmidt et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Systematic review: the role of tacrolimus in the management of Crohn’s disease

(2011) K. McSharry et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Understanding the Use of Immunosuppressive Agents in the Clinical Management of IBD

(2011) O. R. Waters et al.   CURRENT DRUG TARGETS

Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis

(2011) Haruhiko Ogata et al.   INFLAMMATORY BOWEL DISEASES

Immunosuppressive effects of tacrolimus on macrophages ameliorate experimental colitis

(2010) Takuya Yoshino et al.   INFLAMMATORY BOWEL DISEASES

Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis

(2008) S. YAMAMOTO et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

(2008) William J. Sandborn et al.   GASTROENTEROLOGY

The effect of tacrolimus (FK-506) on Japanese patients with refractory Crohn’s disease

(2008) Hiroyuki Tamaki et al.   JOURNAL OF GASTROENTEROLOGY

Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohnʼs disease: A single-center experience

(2007) Aaron Benson et al.   INFLAMMATORY BOWEL DISEASES